Claims
- 1. A compound of formula I, II or III: or a stereoisomer or pharmaceutically acceptable salt form thereof, wherein;A is selected from: —C(O)NHOH, —C(O)NHOR5, —C(O)NHOR6, —N(OH)COR5, —N(OH)CHO, and —CH2SH; ring C is substituted with 0-1 R3 and 0-1 R4; R1 is U—X—Y—Z—Ua—Xa—Ya—Za; U is selected from: C(O), C(O)O, C(O)NRa1, S(O)p, and S(O)pNRa1; X is absent or is selected from: C1-10 alkylene, C2-10 alkenylene, and C2-10 alkynylene; Y is absent or is selected from: O, NRa1, S(O)p, and C(O); Z is selected from: a C3-13 carbocycle substituted with 0-5 Rb; and a 5-14 membered heterocycle consisting of carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O)p and substituted with 0-5 Rb; Ua is absent or is selected from: O, NRa1, C(O), C(O)O, OC(O), C(O)NRa1, NRa1C(O), OC(O)O, OC(O)NRa1, NRa1C(O)O, NRa1C(O)NRa1, S(O)p, S(O)pNRa1, NRa1S(O)p, and NRa1SO2NRa1; Xa is absent or is selected from: C1-4 alkylene, C2-4 alkenylene, and C2-4 alkynylene; Ya is absent or is selected from: O, NRa1, S(O)p, and C(O); provided that Ua—Xa—Ya forms a spacer of two or more atoms, other than —CH═CH— or —C≡C—; Za is selected from: a C3-13 carbocycle substituted with 0-5 Rc; and a 5-14 membered heterocycle consisting of carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O)p and substituted with 0-5 Rc; provided that U, Y, Z, Ua, Ya, and Za do not combine to form a N—N, N—O, O—N, O—O, S(O)p—O, O—S(O)p or S(O)p—S(O)p group; R3 is selected from: H, C1-6 alkyl substituted with 0-1 Rb, C2-6 alkenyl substituted with 0-1 Rb, C2-6 alkynyl substituted with 0-1 Rb, C3-10 carbocycle substituted with 0-2 Rb, —(CH2)r—C3-10 carbocycle substituted with 0-2 Rb, and —(CH2)r-5-10 membered heterocycle consisting of carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O)p and substituted with 0-2 Rb; R4 is selected from: H, C1-6 alkyl substituted with 0-1 Rb, C2-6 alkenyl substituted with 0-1 Rb, C2-6 alkynyl substituted with 0-1 Rb, ORa, Cl, F, Br, I, ═O, —CN, NO2, NRaRa1, C(O)Ra, C(O)ORa, C(O)NRaRa1, NRaC(O)Ra, C(S)NRaRa1, NRaC(O)NRaRa1, OC(O)NRaRa1, NRaC(O)ORa, S(O)2NRaRa1, NRaS(O)2Ra3, NRaS(O)2NRaRa1, OS(O)2NRaRa1, NRaS(O)2Ra3, S(O)pRa3, CF3, OCF3, and CF2CF3; Ra, at each occurrence, is independently selected from: H and C1-6 alkyl; Ra1, at each occurrence, is independently selected from: H, C1-6 alkyl substituted with 0-1 Rc1, C2-6 alkenyl substituted with 0-1 Rc1, C2-6 alkynyl substituted with 0-1 Rc1, and —(CH2)r-3-8 membered carbocyclic or heterocyclic ring consisting of carbon atoms and 0-2 ring heteroatoms selected from N, NRa2, O, and S(O)p and substituted with 0-3 Rc1; alternatively, Ra and Ra1 when attached to a nitrogen are taken together with the nitrogen to which they are attached form a 5 or 6 membered heterocycle consisting of carbon atoms and from 0-1 additional heteroatoms selected from N, NRa2, O, and S(O)p; Ra2, at each occurrence, is independently selected from: C1-4 alkyl, phenyl, and benzyl; Ra3, at each occurrence, is independently selected from: H, C1-6 alkyl substituted with 0-1 Rc1, C2-6 alkenyl substituted with 0-1 Rc1, C2-6 alkynyl substituted with 0-1 Rc1, —(CH2)r-3-8 membered carbocyclic or heterocyclic ring consisting of carbon atoms and 0-2 ring heteroatoms selected from N, NRa2, O, and S(O)p and substituted with 0-3 Rc1; Rb, at each occurrence, is independently selected from: C1-6 alkyl substituted with 0-1 Rc1, ORa, Cl, F, Br, I, ═O, —CN, NO2, NRaRa1, C(O)Ra, C(O)ORa, C(O)NRaRa1, NRaC(O)Ra, C(S)NRaRa1, NRaC(O)NRaRa1, OC(O)NRaRa1, NRaC(O)ORa, S(O)2NRaRa1, NRaS(O)2Ra3, NRaS(O)2NRaRa1, OS(O)2NRaRa1, NRaS(O)2Ra3, S(O)pRa3, CF3, OCF3, CF2CF3, CHF2, CH2F, and phenyl; Rc, at each occurrence, is independently selected from: H, C1-6 alkyl substituted with 0-2 Rc1, C2-6 alkenyl substituted with 0-2 Rc1, C2-6 alkynyl substituted with 0-2 Rc1, ORa, Cl, F, Br, I, ═O, —CN, NO2, CF3, CF2CF3, CH2F, CHF2, (CRaRa1)nNRaRa1, (CRaRa1)nC(═NCN)NRaRa1, (CRaRa1)nC(═NRa)NRaRa1, (CRaRa1)nC(═NORa)NRaRa1, (CRaRa1)nC(O)NRaOH, (CRaRa1)nC(O)Ra1, (CRaRa1)nC(O)ORa1, (CRaRa1)nC(S)ORa1, (CRaRa1)nC(O)NRaRa1, (CRaRa1)nNRaC(O)Ra1, (CRaRa1)nC(S)NRaRa1, (CRaRa1)nOC(O)NRaRa1, (CRaRa1)nNRaC(O)ORa1, (CRaRa1)nNRaC(O)NRaRa1, (CRaRa1)nS(O)pRa3, (CRaRa1)nSO2NRaRa1, (CRaRa1)nNRaSO2Ra3, (CRaRa1)nNRaSO2NRaRa1, —(CRaRa1)n—C3-10 carbocycle substituted with 0-2 Rc1, and —(CRaRa1)n-5-14 membered heterocycle consisting of carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O)p and substituted with 0-2 Rc1; Rc1, at each occurrence, is independently selected from: H, C1-4 alkyl, ORa, Cl, F, Br, I, ═O, CF3, —CN, NO2, C(O)Ra, C(O)ORa, C(O)NRaRa, and S(O)pRa; R5, at each occurrence, is selected from: C1-10 alkyl substituted with 0-2 Rb, and C1-8 alkyl substituted with 0-2 Re; Re, at each occurrence, is selected from: phenyl substituted with 0-2 Rb and biphenyl substituted with 0-2 Rb; R6, at each occurrence, is selected from: phenyl, naphthyl, C1-10 alkyl-phenyl-C1-6 alkyl-, C3-11 cycloalkyl, C1-6 alkylcarbonyloxy-C1-3 alkyl-, C1-6 alkoxycarbonyloxy-C1-3 alkyl-, C2-10 alkoxycarbonyl, C3-6 cycloalkylcarbonyloxy-C1-3 alkyl-, C3-6 cycloalkoxycarbonyloxy-C1-3 alkyl-, C3-6 cycloalkoxycarbonyl, phenoxycarbonyl, phenyloxycarbonyloxy-C1-3 alkyl-, phenylcarbonyloxy-C1-3 alkyl-, C1-6 alkoxy-C1-6 alkylcarbonyloxy-C1-3 alkyl-, [5-(C1-C5 alkyl)-1,3-dioxa-cyclopenten-2-one-yl]methyl, [5-(Ra)-1,3-dioxa-cyclopenten-2-one-yl]methyl, (5-aryl-1,3-dioxa-cyclopenten-2-one-yl)methyl, —C1-10 alkyl-NR7R7a, —CH(R8)OC(═O)R9, and —CH(R8)OC(═O)OR9; R7 is selected from: H, C1-10 alkyl, C2-6 alkenyl, C3-6 cycloalkyl-C1-3 alkyl-, and phenyl-C1-6 alkyl-; R7a is selected from H, C1-10 alkyl, C2-6 alkenyl, C3-6 cycloalkyl-C1-3 alkyl-, and phenyl-C1-6 alkyl-; R8 is selected from H and C1-4 linear alkyl; R9 is selected from H, C1-8 alkyl substituted with 1-2 Rf, C3-8 cycloalkyl substituted with 1-2 Rf, and phenyl substituted with 0-2 Rb; Rf, at each occurrence, is selected from: C1-4 alkyl, C3-8 cycloalkyl, C1-5 alkoxy, and phenyl substituted with 0-2 Rb; n, at each occurrence, is selected from: 0, 1, 2, 3, and 4; p, at each occurrence, is selected from: 0, 1, and 2; and r, at each occurrence, is selected from: 0, 1, 2, 3, and 4; provided that: (iv) when U is SO2, then Ua—Xa—Ya is other than —OCH2—C≡C—, —NHCH2—C≡C—, —CH2CH2—C≡C— or —SCH2—C≡C—; (v) when U is SO2 and Z is phenyl, then Ua is other than OC(O).
- 2. A compound according to claim 1, wherein;A is selected from: —C(O)NHOH, —C(O)NHOR5, —C(O)NHOR6, —N(OH)COR5, and —N(OH)CHO; X is absent or is selected from: C1-4 alkylene, C2-4 alkenylene, and C2-4 alkynylene; Y is absent; Z is selected from: a C3-11 carbocycle substituted with 0-5 Rb; and a 5-11 membered heterocycle consisting of carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O)p and substituted with 0-5 Rb; Ua is absent or is selected from: O, NRa1, C(O), C(O)O, C(O)NRa1, NRa1C(O), S(O)p, and S(O)pNRa1; Xa is absent or is selected from: C1-4 alkylene, C2 alkenylene, and C2 alkynylene; Ya is absent or is selected from: O and NRa1; provided that Ua—Xa—Ya forms a spacer of two or more atoms, other than —CH═CH— or —C≡C—; Za is selected from: a C3-13 carbocycle substituted with 0-5 Rc; and a 5-10 membered heterocycle consisting of carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O)p and substituted with 0-5 Rc; provided that U, Z, Ua, Ya, and Za do not combine to form a N—N, N—O, O—N, O—O, S(O)p—O, O—S(O)p or S(O)p—S(O)p group; R3 is selected from: H, C1-6 alkyl substituted with 0-1 Rb, C2-6 alkenyl substituted with 0-1 Rb, C3-6 carbocycle substituted with 0-2 Rb, —CH2—C3-6 carbocycle substituted with 0-2 Rb, a 5-6 membered heterocycle consisting of carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O)p and substituted with 0-2 Rb, and —CH2-5-6 membered heterocycle consisting of carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O)p and substituted with 0-2 Rb; Ra, at each occurrence, is independently selected from: H and C1-4 alkyl; Ra1, at each occurrence, is independently selected from: H, C1-4 alkyl, phenyl and benzyl; alternatively, Ra and Ra1 when attached to a nitrogen are taken together with the nitrogen to which they are attached form a 5 or 6 membered heterocycle consisting of carbon atoms and from 0-1 additional heteroatoms selected from N, NRa2, O, and S(O)p; Rb, at each occurrence, is independently selected from: C1-6 alkyl, ORa, Cl, F, Br, ═O, —CN, NRaRa1, C(—O)Ra, C(O)ORa, C(O)NRaRa1, NRaC(O)Ra, S(O)2NRaRa1, S(O)pRa3, CF3, and OCF3; Rc, at each occurrence, is independently selected from: C1-6 alkyl substituted with 0-1 Rc1, C2-6 alkenyl substituted with 0-1 Rc1, C2-6 alkynyl substituted with 0-1 Rc1, ORa, Cl, F, Br, ═O, —CN, NRaRa1, CF3, (CRaRa1)nC(O)Ra1, (CRaRa1)nC(O)ORa1, (CRaRa1)nC(O)NRaRa1, (CRaRa1)nS(O)pRa3, (CRaRa1)nSO2NRaRa1, C3-6 carbocycle and a 5-6 membered heterocycle comprising carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O)p; R5, at each occurrence, is selected from: C1-6 alkyl substituted with 0-2 Rb, and C1-4 alkyl substituted with 0-2 Re; R7 is selected from: H, C1-6 alkyl, C2-6 alkenyl, C3-6 cycloalkyl-C1-3 alkyl-, and phenyl-C1-6 alkyl-; R7a is selected from: H, C1-6 alkyl, C2-6 alkenyl, C3-6 cycloalkyl-C1-3 alkyl-, and phenyl-C1-6 alkyl-; and R9 is selected from: H, C1-6 alkyl substituted with 1-2 Rf, C3-6 cycloalkyl substituted with 1-2 Rf, and phenyl substituted with 0-2 Rb.
- 3. A compound according to claim 2, wherein;A is selected from: —C(O)NHOH, and —N(OH)CHO; U—X is SO2, C(O), or C(O)CH2; Z is phenyl substituted with 0-3 Rb or pyridyl substituted with 0-3 Rb; Ua is absent or is selected from: O, NRa1, C(O), C(O)NRa1, S(O)p, and S(O)pNRa1; Xa is absent or is selected from: C1-4 alkylene, C2 alkenylene, and C2 alkynylene; provided that Ua—Xa—Ya forms a spacer of two or more atoms and is other than —CH═CH— or —C≡C—; Za is a C5-6 carbocycle substituted with 0-3 Rc or a 5-10 membered heteroaryl containing from 1-4 heteroatoms selected from the group consisting of N, O, and S(O)p and substituted with 0-3 Rc; provided that Z, Ua, Ya, and Za do not combine to form a N—N, N—O, O—N, O—O, S(O)p—O, O—S(O)p or S(O)p—S(O)p group; Ra, at each occurrence, is independently selected from: H and C1-4 alkyl; Ra1, at each occurrence, is independently selected from: H, C1-4 alkyl, phenyl and benzyl; Rb, at each occurrence, is independently selected from: C1-4 alkyl, ORa, Cl, F, ═O, NRaRa1, C(O)Ra, C(O)ORa, C(O)NRaRa1, S(O)2NRaRa1, S(O)pRa3, and CF3; Rc, at each occurrence, is independently selected from: C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, ORa, Cl, F, Br, ═O, NRaRa1, CF3, (CRaRa1)nC(O)Ra1, (CRaRa1)nC(O)ORa, (CRaRa1)nC(O)NRaRa1, (CRaRa1)nS(O)pRa3, (CRaRa1)nSO2NRaRa1, and phenyl; and R5, at each occurrence, is selected from: C1-4 alkyl substituted with 0-2 Rb, and C1-4 alkyl substituted with 0-2 Re.
- 4. A compound according to claim 3, wherein;A is —C(O)NHOH; Z is phenyl substituted with 0-1 Rb or pyridyl substituted with 0-1 Rb; Ua is absent or is O; Xa is absent or is CH2 or CH2CH2; Ya is absent or is O; provided that Ua—Xa—Ya forms a spacer of two or more atoms, other than —CH═CH— or —C≡C—; Za is selected from: phenyl substituted with 0-3 Rc, pyridyl substituted with 0-3 Rc, and quinolinyl substituted with 0-3 Rc; provided that Z, Ua, Ya, and Za do not combine to form a N—N, N—O, O—N, or O—O group; Ra, at each occurrence, is independently selected from: H, CH3, and CH2CH3; Ra1, at each occurrence, is independently selected from: H, CH3, and CH2CH3; Ra2, at each occurrence, is independently selected from: H, CH3, and CH2CH3; Rc, at each occurrence, is independently selected from: C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, ORa, Cl, F, Br, ═O, NRaRa1, CF3, (CRaRa1)nC(O)Ra1, (CRaRa1)nC(O)ORa, (CRaRa1)nC(O)NRaRa1, (CRaRa1)nS(O)pRa3, and (CRaRa1)nSO2NRaRa1; r, at each occurrence, is selected from 0, 1, 2, and 3; and, n, at each occurrence, is selected from 0, 1, 2, and 3.
- 5. A compound according to claim 1, wherein the compound is selected from the group:N-hydroxy-6-({4-[(2-methyl-4-quinolinyl)methoxy]phenyl}acetyl)-5,6,7,8-tetrahydropyrido[3,4-b]-pyrazine-7-carboxamide; and N-hydroxy-6-({4-[(2-methyl-4-quinolinyl)methoxy]phenyl}sulfonyl)-5,6,7,8-tetrahydropyrido[3,4-b]pyrazine-7-carboxamide; or a pharmaceutically acceptable salt form thereof.
- 6. A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt form thereof.
- 7. A method of treating a disease or condition selected from age related macular degeneration, alcoholic liver disease, allergy, allergic asthma, anorexia, aneurism, aortic aneurism, asthma, atherosclerosis, atopic dermatitis, autoimmune hepatitis, Bechet's disease, cachexia, calcium pyrophosphate dihydrate deposition disease, chronic fatigue syndrome, chronic obstruction pulmonary disease, congestive heart failure, corneal ulceration, Crohn's disease, enteropathic arthropathy, Felty's syndrome, fever, fibromyalgia syndrome, fibrotic disease, gingivitis, glucocorticoid withdrawal syndrome, gout, graft versus host disease, hemorrhage, hyperoxic alveolar injury, infectious arthritis, intermittent hydrarthrosis, Lyme disease, meningitis, multiple sclerosis, myasthenia gravis, mycobacterial infection, neovascular glaucoma, osteoarthritis, pelvic inflammatory disease, periodontitis, polymyositis/dermatomyositis, post-ischaemic reperfusion injury, post-radiation asthenia, psoriasis, psoriatic arthritis, pulmonary emphysema, pydoderma gangrenosum, relapsing polychondritis, Reiter's syndrome, rheumatic fever, rheumatoid arthritis, sarcoidosis, scleroderma, sepsis syndrome, Still's disease, shock, Sjogrens syndrome, spondylitis, systemic lupus erythematosus, ulcerative colitis, uveitis, vasculitis, and Wegener's granulomatosis, in a mammal, comprising: administering to the mammal in need of such treatment a therapeutically effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt form thereof.
- 8. A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound according to claim 2 or a pharmaceutically acceptable salt form thereof.
- 9. A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound according to claim 3 or a pharmaceutically acceptable salt form thereof.
- 10. A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound according to claim 4 or a pharmaceutically acceptable salt form thereof.
- 11. A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound according to claim 5 or a pharmaceutically acceptable salt form thereof.
- 12. A method of treating a disease or condition selected from age related macular degeneration, alcoholic liver disease, allergy, allergic asthma, anorexia, aneurism, aortic aneurism, asthma, atherosclerosis, atopic dermatitis, autoimmune hepatitis, Bechet's disease, cachexia, calcium pyrophosphate dihydrate deposition disease, chronic fatigue syndrome, chronic obstruction pulmonary disease, congestive heart failure, corneal ulceration, Crohn's disease, enteropathic arthropathy, Felty's syndrome, fever, fibromyalgia syndrome, fibrotic disease, gingivitis, glucocorticoid withdrawal syndrome, gout, graft versus host disease, hemorrhage, hyperoxic alveolar injury, infectious arthritis, intermittent hydrarthrosis, Lyme disease, meningitis, multiple sclerosis, myasthenia gravis, mycobacterial infection, neovascular glaucoma, osteoarthritis, pelvic inflammatory disease, periodontitis, polymyositis/dermatomyositis, post-ischaemic reperfusion injury, post-radiation asthenia, psoriasis, psoriatic arthritis, pulmonary emphysema, pydoderma gangrenosum, relapsing polychondritis, Reiter's syndrome, rheumatic fever, rheumatoid arthritis, sarcoidosis, scleroderma, sepsis syndrome, Still's disease, shock, Sjogren's syndrome, spondylitis, systemic lupus erythematosus, ulcerative colitis, uveitis, vasculitis, and Wegener's granulomatosis, in a mammal, comprising: administering to the mammal in need of such treatment a therapeutically effective amount of a compound according to claim 2 or a pharmaceutically acceptable salt form thereof.
- 13. A method of treating a disease or condition selected from age related macular degeneration, alcoholic liver disease, allergy, allergic asthma, anorexia, aneurism, aortic aneurism, asthma, atherosclerosis, atopic dermatitis, autoimmune hepatitis, Bechet's disease, cachexia, calcium pyrophosphate dihydrate deposition disease, chronic fatigue syndrome, chronic obstruction pulmonary disease, congestive heart failure, corneal ulceration, Crohn's disease, enteropathic arthropathy, Felty's syndrome, fever, fibromyalgia syndrome, fibrotic disease, gingivitis, glucocorticoid withdrawal syndrome, gout, graft versus host disease, hemorrhage, hyperoxic alveolar injury, infectious arthritis, intermittent hydrarthrosis, Lyme disease, meningitis, multiple sclerosis, myasthenia gravis, mycobacterial infection, neovascular glaucoma, osteoarthritis, pelvic inflammatory disease, periodontitis, polymyositis/dermatomyositis, post-ischaemic reperfusion injury, post-radiation asthenia, psoriasis, psoriatic arthritis, pulmonary emphysema, pydoderma gangrenosum, relapsing polychondritis, Reiter's syndrome, rheumatic fever, rheumatoid arthritis, sarcoidosis, scleroderma, sepsis syndrome, Still's disease, shock, Sjogren's syndrome, spondylitis, systemic lupus erythematosus, ulcerative colitis, uveitis, vasculitis, and Wegener's granulomatosis, in a mammal, comprising: administering to the mammal in need of such treatment a therapeutically effective amount of a compound according to claim 3 or a pharmaceutically acceptable salt form thereof.
- 14. A method of treating a disease or condition selected from age related macular degeneration, alcoholic liver disease, allergy, allergic asthma, anorexia, aneurism, aortic aneurism, asthma, atherosclerosis, atopic dermatitis, autoimmune hepatitis, Bechet's disease, cachexia, calcium pyrophosphate dihydrate deposition disease, chronic fatigue syndrome, chronic obstruction pulmonary disease, congestive heart failure, corneal ulceration, Crohn's disease, enteropathic arthropathy, Felty's syndrome, fever, fibromyalgia syndrome, fibrotic disease, gingivitis, glucocorticoid withdrawal syndrome, gout, graft versus host disease, hemorrhage, hyperoxic alveolar injury, infectious arthritis, intermittent hydrarthrosis, Lyme disease, meningitis, multiple sclerosis, myasthenia gravis, mycobacterial infection, neovascular glaucoma, osteoarthritis, pelvic inflammatory disease, periodontitis, polymyositis/dermatomyositis, post-ischaemic reperfusion injury, post-radiation asthenia, psoriasis, psoriatic arthritis, pulmonary emphysema, pydoderma gangrenosum, relapsing polychondritis, Reiter's syndrome, rheumatic fever, rheumatoid arthritis, sarcoidosis, scleroderma, sepsis syndrome, Still's disease, shock, Sjogren's syndrome, spondylitis, systemic lupus erythematosus, ulcerative colitis, uveitis, vasculitis, and Wegener's granulomatosis, in a mammal, comprising: administering to the mammal in need of such treatment a therapeutically effective amount of a compound according to claim 4 or a pharmaceutically acceptable salt form thereof.
- 15. A method of treating a disease or condition selected from age related macular degeneration, alcoholic liver disease, allergy, allergic asthma, anorexia, aneurism, aortic aneurism, asthma, atherosclerosis, atopic dermatitis, autoimmune hepatitis, Bechet's disease, cachexia, calcium pyrophosphate dihydrate deposition disease, chronic fatigue syndrome, chronic obstruction pulmonary disease, congestive heart failure, corneal ulceration, Crohn's disease, enteropathic arthropathy, Felty's syndrome, fever, fibromyalgia syndrome, fibrotic disease, gingivitis, glucocorticoid withdrawal syndrome, gout, graft versus host disease, hemorrhage, hyperoxic alveolar injury, infectious arthritis, intermittent hydrarthrosis, Lyme disease, meningitis, multiple sclerosis, myasthenia gravis, mycobacterial infection, neovascular glaucoma, osteoarthritis, pelvic inflammatory disease, periodontitis, polymyositis/dermatomyositis, post-ischaemic reperfusion injury, post-radiation asthenia, psoriasis, psoriatic arthritis, pulmonary emphysema, pydoderma gangrenosum, relapsing polychondritis, Reiter's syndrome, rheumatic fever, rheumatoid arthritis, sarcoidosis, scleroderma, sepsis syndrome, Still's disease, shock, Sjogren's syndrome, spondylitis, systemic lupus erythematosus, ulcerative colitis, uveitis, vasculitis, and Wegener's granulomatosis, in a mammal, comprising: administering to the mammal in need of such treatment a therapeutically effective amount of a compound according to claim 5 or a pharmaceutically acceptable salt form thereof.
CROSS-REFERENCE TO RELATED APPLICATIONS
This appilcation claims the priority benefit of U.S. Provisional Application No. 60/313,052, filed Aug. 17, 2001, which is expressly incorporated fully herein by reference.
US Referenced Citations (7)
Number |
Name |
Date |
Kind |
5506242 |
MacPherson et al. |
Apr 1996 |
A |
5552419 |
MacPherson et al. |
Sep 1996 |
A |
5672615 |
MacPherson et al. |
Sep 1997 |
A |
5866587 |
Nanteuil et al. |
Feb 1999 |
A |
5962471 |
Schudok |
Oct 1999 |
A |
6225311 |
Levin et al. |
May 2001 |
B1 |
6339092 |
Nanteuil et al. |
Jan 2002 |
B1 |
Foreign Referenced Citations (4)
Number |
Date |
Country |
WO 9718194 |
May 1997 |
WO |
WO 9808850 |
Mar 1998 |
WO |
WO 0023443 |
Apr 2000 |
WO |
WO 0044730 |
Aug 2000 |
WO |
Non-Patent Literature Citations (6)
Entry |
Chalmers (TiPS vol. 17, pp. 166-172 Apr. 1996.* |
Robert A. Greenwald {Annals of New York Academy of Sciences 878:413-419 (1999)}.* |
Coussens et al. {SCIENCE vol. 295, Mar. 29, pp. 2387-2392, (2002)}.* |
Moro et al. (Neurosignals 2003; 12:53-58).* |
Skiles et al. {Current Medicinal Chemistry, 8, 425-474 (2001)}.* |
Lou et al. {Mini Reviews in Medicinal Chemistry, 2003, 3, 609-620}. |
Provisional Applications (1)
|
Number |
Date |
Country |
|
60/313052 |
Aug 2001 |
US |